Toledo CDX Model

The Toledo cell line is derived from human diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma. DLBCL is characterized by its aggressive nature and the rapid proliferation of large B-lymphocytes in lymph nodes and other organs. The Toledo cell line serves as a fundamental tool for delving into the biology, progression, and therapeutic landscapes associated with DLBCL. Capturing characteristic molecular signatures and genetic alterations prevalent in DLBCL patients, Toledo is of pivotal significance in preclinical research. Its behavior, in both in vitro and in vivo settings, provides comprehensive insights into tumor growth kinetics, potential for metastasis, and responses to therapeutic agents. The Toledo model is extensively employed by researchers to decode the molecular and cellular dynamics of DLBCL, to evaluate the potency of novel therapeutic compounds, and to explore potential mechanisms of resistance to existing treatments.

Model Details

Cancer Location: Lymph Node
Cancer Type: Diffuse Large B-Cell Lymphoma
Model Name: Toledo
Mouse Strain: NOG, SCID Beige
Treatment Data Available: Chemotherapy (Ventoclax)

Toledo Growth Curves

Toledo CDX Model

Growth of subcutaneous Toledo  in NOG mice (n=5 mice)

Request Additional CDX Model Data


Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.